| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cloud Computing | 5 | 2024 | 14 | 2.490 |
Why?
|
| Spinal Cord Injuries | 9 | 2023 | 115 | 2.360 |
Why?
|
| Genomics | 13 | 2024 | 857 | 2.080 |
Why?
|
| Neoplasms | 20 | 2025 | 3242 | 1.990 |
Why?
|
| Software | 10 | 2023 | 698 | 1.970 |
Why?
|
| Databases, Factual | 9 | 2025 | 1014 | 1.780 |
Why?
|
| Biomedical Research | 9 | 2024 | 442 | 1.620 |
Why?
|
| Information Dissemination | 7 | 2024 | 126 | 1.580 |
Why?
|
| Genome, Human | 8 | 2021 | 823 | 1.410 |
Why?
|
| Neuroprotective Agents | 2 | 2023 | 102 | 1.410 |
Why?
|
| Electronic Health Records | 3 | 2024 | 373 | 1.300 |
Why?
|
| Cervical Cord | 2 | 2023 | 16 | 1.000 |
Why?
|
| Datasets as Topic | 3 | 2017 | 81 | 0.920 |
Why?
|
| Riluzole | 2 | 2023 | 17 | 0.900 |
Why?
|
| Veterans | 2 | 2024 | 100 | 0.900 |
Why?
|
| Databases, Genetic | 3 | 2021 | 283 | 0.880 |
Why?
|
| Precision Medicine | 10 | 2025 | 456 | 0.850 |
Why?
|
| Neck Injuries | 1 | 2023 | 15 | 0.800 |
Why?
|
| Vocabulary, Controlled | 1 | 2023 | 12 | 0.790 |
Why?
|
| National Cancer Institute (U.S.) | 6 | 2024 | 72 | 0.780 |
Why?
|
| Genome, Bacterial | 3 | 2022 | 159 | 0.770 |
Why?
|
| Biomarkers, Tumor | 5 | 2025 | 1670 | 0.770 |
Why?
|
| Computational Biology | 6 | 2019 | 587 | 0.760 |
Why?
|
| Data Accuracy | 2 | 2022 | 32 | 0.760 |
Why?
|
| Medical Informatics | 2 | 2024 | 48 | 0.750 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2023 | 153 | 0.730 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2022 | 12 | 0.730 |
Why?
|
| Whole Genome Sequencing | 2 | 2022 | 109 | 0.720 |
Why?
|
| Antitubercular Agents | 1 | 2022 | 61 | 0.710 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2022 | 52 | 0.700 |
Why?
|
| Liquid Biopsy | 6 | 2025 | 48 | 0.700 |
Why?
|
| Medical Oncology | 4 | 2024 | 408 | 0.690 |
Why?
|
| Humans | 74 | 2025 | 95992 | 0.670 |
Why?
|
| Drosophila melanogaster | 6 | 2014 | 634 | 0.640 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2022 | 208 | 0.610 |
Why?
|
| DNA Mutational Analysis | 2 | 2021 | 548 | 0.600 |
Why?
|
| Disease | 2 | 2017 | 93 | 0.590 |
Why?
|
| Gene Regulatory Networks | 3 | 2010 | 321 | 0.570 |
Why?
|
| Mutation | 6 | 2024 | 4374 | 0.550 |
Why?
|
| Spatial Analysis | 1 | 2017 | 10 | 0.530 |
Why?
|
| Information Storage and Retrieval | 4 | 2023 | 127 | 0.530 |
Why?
|
| Schools, Medical | 3 | 2024 | 144 | 0.520 |
Why?
|
| Algorithms | 6 | 2023 | 2018 | 0.510 |
Why?
|
| Data Collection | 1 | 2018 | 381 | 0.510 |
Why?
|
| Neuroblastoma | 2 | 2019 | 401 | 0.510 |
Why?
|
| Genome-Wide Association Study | 4 | 2020 | 1766 | 0.480 |
Why?
|
| United States | 15 | 2024 | 7785 | 0.430 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 778 | 0.410 |
Why?
|
| Computer Systems | 1 | 2014 | 79 | 0.410 |
Why?
|
| Health Priorities | 3 | 2023 | 28 | 0.410 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 3 | 2016 | 65 | 0.410 |
Why?
|
| Evolution, Molecular | 1 | 2020 | 891 | 0.400 |
Why?
|
| Prostatic Neoplasms | 1 | 2024 | 1798 | 0.380 |
Why?
|
| Data Mining | 2 | 2014 | 44 | 0.380 |
Why?
|
| Gene Expression Regulation | 5 | 2021 | 2059 | 0.370 |
Why?
|
| DNA Methylation | 4 | 2021 | 702 | 0.370 |
Why?
|
| Systems Biology | 1 | 2012 | 47 | 0.350 |
Why?
|
| Databases, Nucleic Acid | 1 | 2011 | 44 | 0.340 |
Why?
|
| Molecular Sequence Annotation | 3 | 2021 | 78 | 0.330 |
Why?
|
| Models, Statistical | 3 | 2018 | 594 | 0.330 |
Why?
|
| Phenotype | 5 | 2022 | 2575 | 0.330 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2025 | 1319 | 0.330 |
Why?
|
| Transcription Factors | 7 | 2014 | 1729 | 0.320 |
Why?
|
| Spinal Cord Diseases | 3 | 2021 | 90 | 0.320 |
Why?
|
| User-Computer Interface | 3 | 2021 | 196 | 0.300 |
Why?
|
| Models, Molecular | 2 | 2004 | 1376 | 0.290 |
Why?
|
| Base Sequence | 5 | 2021 | 2341 | 0.290 |
Why?
|
| Models, Biological | 2 | 2021 | 1810 | 0.290 |
Why?
|
| Reproducibility of Results | 6 | 2023 | 2885 | 0.270 |
Why?
|
| Genome, Insect | 3 | 2014 | 78 | 0.260 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 1 | 2007 | 9 | 0.260 |
Why?
|
| Computer Security | 3 | 2019 | 17 | 0.250 |
Why?
|
| Sequence Analysis, DNA | 3 | 2018 | 911 | 0.250 |
Why?
|
| Computer Graphics | 1 | 2006 | 102 | 0.240 |
Why?
|
| Genome | 1 | 2009 | 407 | 0.240 |
Why?
|
| Multiple Sclerosis | 4 | 2002 | 264 | 0.240 |
Why?
|
| Male | 18 | 2025 | 45792 | 0.240 |
Why?
|
| Diagnostic Imaging | 2 | 2025 | 476 | 0.240 |
Why?
|
| Disease Susceptibility | 1 | 2007 | 220 | 0.240 |
Why?
|
| Cerebrovascular Circulation | 2 | 2007 | 243 | 0.230 |
Why?
|
| Health Information Interoperability | 1 | 2025 | 7 | 0.230 |
Why?
|
| Data Curation | 1 | 2025 | 10 | 0.230 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 313 | 0.220 |
Why?
|
| Specimen Handling | 2 | 2025 | 109 | 0.220 |
Why?
|
| Computer Communication Networks | 2 | 2016 | 24 | 0.210 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2020 | 2474 | 0.210 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2007 | 277 | 0.210 |
Why?
|
| Chemistry | 1 | 2004 | 54 | 0.210 |
Why?
|
| Organic Chemicals | 1 | 2004 | 37 | 0.210 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 1018 | 0.210 |
Why?
|
| Recovery of Function | 4 | 2023 | 348 | 0.200 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 3 | 2014 | 167 | 0.200 |
Why?
|
| Copper | 1 | 2023 | 81 | 0.200 |
Why?
|
| Halomonadaceae | 2 | 2013 | 4 | 0.190 |
Why?
|
| Decompression, Surgical | 2 | 2023 | 168 | 0.190 |
Why?
|
| Chromatin | 5 | 2014 | 445 | 0.190 |
Why?
|
| Internet | 3 | 2017 | 340 | 0.190 |
Why?
|
| Terminology as Topic | 1 | 2004 | 227 | 0.190 |
Why?
|
| Brain | 6 | 2016 | 2479 | 0.190 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2003 | 3642 | 0.180 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2003 | 137 | 0.180 |
Why?
|
| Chromatin Immunoprecipitation | 3 | 2011 | 142 | 0.180 |
Why?
|
| Circulating Tumor DNA | 1 | 2023 | 76 | 0.180 |
Why?
|
| Pharmaceutical Preparations | 1 | 2003 | 97 | 0.170 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2022 | 153 | 0.170 |
Why?
|
| Female | 19 | 2025 | 49980 | 0.170 |
Why?
|
| Metabolic Clearance Rate | 1 | 2021 | 119 | 0.170 |
Why?
|
| Half-Life | 1 | 2021 | 99 | 0.170 |
Why?
|
| Radiographic Image Enhancement | 1 | 2023 | 467 | 0.170 |
Why?
|
| Prognosis | 4 | 2023 | 3993 | 0.170 |
Why?
|
| 5-Methylcytosine | 2 | 2019 | 122 | 0.170 |
Why?
|
| Disease Progression | 1 | 2025 | 1561 | 0.160 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2021 | 155 | 0.160 |
Why?
|
| Viruses | 1 | 2021 | 75 | 0.160 |
Why?
|
| Chromothripsis | 1 | 2020 | 9 | 0.160 |
Why?
|
| Academic Success | 1 | 2020 | 11 | 0.160 |
Why?
|
| Skin Neoplasms | 1 | 2025 | 621 | 0.160 |
Why?
|
| Promoter Regions, Genetic | 3 | 2020 | 996 | 0.160 |
Why?
|
| DNA Copy Number Variations | 1 | 2021 | 192 | 0.160 |
Why?
|
| Curriculum | 1 | 2024 | 616 | 0.160 |
Why?
|
| Brain Neoplasms | 2 | 2025 | 848 | 0.150 |
Why?
|
| Veterans Health | 1 | 2019 | 19 | 0.150 |
Why?
|
| Oncogenes | 1 | 2020 | 100 | 0.150 |
Why?
|
| Transcriptome | 1 | 2025 | 766 | 0.150 |
Why?
|
| Health Status Disparities | 1 | 2022 | 221 | 0.150 |
Why?
|
| Telomerase | 1 | 2020 | 68 | 0.150 |
Why?
|
| Mutagenesis | 1 | 2020 | 202 | 0.150 |
Why?
|
| Machine Learning | 4 | 2025 | 348 | 0.150 |
Why?
|
| Lung Neoplasms | 2 | 2024 | 2384 | 0.150 |
Why?
|
| Cellular Senescence | 1 | 2020 | 106 | 0.150 |
Why?
|
| Telomere | 1 | 2020 | 121 | 0.150 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 372 | 0.150 |
Why?
|
| Epigenomics | 1 | 2019 | 109 | 0.150 |
Why?
|
| Ecosystem | 2 | 2023 | 396 | 0.150 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 401 | 0.140 |
Why?
|
| Students, Medical | 2 | 2024 | 455 | 0.140 |
Why?
|
| Access to Information | 1 | 2018 | 29 | 0.140 |
Why?
|
| RNA Splicing | 1 | 2020 | 159 | 0.140 |
Why?
|
| Meta-Analysis as Topic | 1 | 2018 | 84 | 0.140 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2019 | 94 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 3 | 2024 | 1096 | 0.140 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 484 | 0.140 |
Why?
|
| Mexican Americans | 1 | 2017 | 70 | 0.130 |
Why?
|
| Quantitative Trait Loci | 2 | 2018 | 632 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 1966 | 0.130 |
Why?
|
| Cohort Studies | 2 | 2022 | 3115 | 0.130 |
Why?
|
| Pets | 1 | 2017 | 10 | 0.130 |
Why?
|
| Neurosurgical Procedures | 1 | 2020 | 356 | 0.130 |
Why?
|
| Double-Blind Method | 1 | 2021 | 1792 | 0.130 |
Why?
|
| Models, Genetic | 2 | 2013 | 984 | 0.130 |
Why?
|
| Research | 1 | 2018 | 265 | 0.130 |
Why?
|
| Germ-Line Mutation | 1 | 2020 | 382 | 0.130 |
Why?
|
| Middle Aged | 9 | 2023 | 28299 | 0.130 |
Why?
|
| Pharmacogenomic Testing | 1 | 2017 | 107 | 0.120 |
Why?
|
| Computing Methodologies | 1 | 2016 | 9 | 0.120 |
Why?
|
| Hemiptera | 2 | 2013 | 7 | 0.120 |
Why?
|
| Pandemics | 1 | 2022 | 880 | 0.120 |
Why?
|
| Time Factors | 2 | 2024 | 5593 | 0.120 |
Why?
|
| Phylogeny | 1 | 2022 | 1277 | 0.120 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 539 | 0.120 |
Why?
|
| MicroRNAs | 1 | 2021 | 591 | 0.120 |
Why?
|
| Dogs | 1 | 2017 | 718 | 0.120 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2016 | 76 | 0.120 |
Why?
|
| DNA, Neoplasm | 1 | 2016 | 272 | 0.120 |
Why?
|
| Computer Simulation | 3 | 2025 | 1158 | 0.110 |
Why?
|
| White Matter | 1 | 2016 | 96 | 0.110 |
Why?
|
| DNA, Bacterial | 2 | 2013 | 253 | 0.110 |
Why?
|
| Retrospective Studies | 3 | 2024 | 10307 | 0.110 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 1144 | 0.110 |
Why?
|
| Quality of Life | 1 | 2023 | 1816 | 0.110 |
Why?
|
| Symbiosis | 2 | 2013 | 133 | 0.110 |
Why?
|
| Treatment Outcome | 4 | 2023 | 9228 | 0.110 |
Why?
|
| Gene Expression | 1 | 2018 | 1319 | 0.110 |
Why?
|
| Genetic Variation | 2 | 2018 | 1424 | 0.110 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2017 | 190 | 0.110 |
Why?
|
| Chromatin Assembly and Disassembly | 2 | 2011 | 81 | 0.100 |
Why?
|
| Erythroid Cells | 1 | 2013 | 16 | 0.100 |
Why?
|
| Systems Integration | 1 | 2014 | 34 | 0.100 |
Why?
|
| Erythropoiesis | 1 | 2013 | 53 | 0.100 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2016 | 298 | 0.100 |
Why?
|
| Cell Proliferation | 1 | 2020 | 1753 | 0.100 |
Why?
|
| Binding Sites | 3 | 2014 | 1167 | 0.100 |
Why?
|
| Neurologic Examination | 1 | 2013 | 130 | 0.100 |
Why?
|
| Metagenomics | 1 | 2014 | 100 | 0.100 |
Why?
|
| Animals | 11 | 2024 | 28901 | 0.100 |
Why?
|
| Incidence | 1 | 2017 | 1723 | 0.100 |
Why?
|
| Public-Private Sector Partnerships | 2 | 2024 | 7 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2012 | 80 | 0.090 |
Why?
|
| Models, Chemical | 2 | 2004 | 187 | 0.090 |
Why?
|
| Prospective Studies | 4 | 2023 | 4690 | 0.090 |
Why?
|
| Transcription, Genetic | 2 | 2014 | 1191 | 0.090 |
Why?
|
| Chromosome Deletion | 1 | 2012 | 223 | 0.090 |
Why?
|
| Biotechnology | 1 | 2012 | 31 | 0.090 |
Why?
|
| Aged | 5 | 2022 | 20927 | 0.090 |
Why?
|
| Uncertainty | 2 | 2023 | 82 | 0.090 |
Why?
|
| Child | 5 | 2019 | 7621 | 0.090 |
Why?
|
| Leukemia, Myeloid | 1 | 2012 | 240 | 0.090 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2016 | 700 | 0.090 |
Why?
|
| Gene Components | 1 | 2011 | 7 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 1347 | 0.090 |
Why?
|
| North America | 2 | 2023 | 199 | 0.090 |
Why?
|
| Quality Control | 1 | 2011 | 125 | 0.080 |
Why?
|
| Forecasting | 1 | 2012 | 317 | 0.080 |
Why?
|
| Gene Expression Profiling | 4 | 2021 | 1533 | 0.080 |
Why?
|
| Conserved Sequence | 1 | 2011 | 215 | 0.080 |
Why?
|
| Research Design | 1 | 2014 | 630 | 0.080 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 2534 | 0.080 |
Why?
|
| RNA, Messenger | 2 | 2017 | 2088 | 0.080 |
Why?
|
| Adult | 10 | 2020 | 28636 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2017 | 1230 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2012 | 447 | 0.080 |
Why?
|
| Radiology | 1 | 2012 | 207 | 0.080 |
Why?
|
| Surveys and Questionnaires | 3 | 2023 | 2860 | 0.070 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 563 | 0.070 |
Why?
|
| RNA-Binding Proteins | 1 | 2011 | 305 | 0.070 |
Why?
|
| Nuclear Proteins | 1 | 2012 | 750 | 0.070 |
Why?
|
| Drosophila Proteins | 2 | 2010 | 523 | 0.070 |
Why?
|
| Disability Evaluation | 2 | 2020 | 171 | 0.070 |
Why?
|
| Cervical Vertebrae | 2 | 2020 | 231 | 0.070 |
Why?
|
| Blood Volume | 1 | 2007 | 47 | 0.060 |
Why?
|
| Breast Neoplasms | 2 | 2018 | 3155 | 0.060 |
Why?
|
| Blood Flow Velocity | 1 | 2007 | 201 | 0.060 |
Why?
|
| Registries | 2 | 2023 | 998 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 2385 | 0.060 |
Why?
|
| Spinal Cord | 2 | 1998 | 253 | 0.060 |
Why?
|
| Spinal Canal | 1 | 1986 | 6 | 0.060 |
Why?
|
| Linear Models | 1 | 2007 | 438 | 0.060 |
Why?
|
| Facial Injuries | 1 | 1985 | 26 | 0.060 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2003 | 325 | 0.060 |
Why?
|
| Pattern Recognition, Automated | 1 | 2006 | 223 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2011 | 1267 | 0.060 |
Why?
|
| Craniocerebral Trauma | 1 | 1985 | 60 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2007 | 909 | 0.060 |
Why?
|
| Bangladesh | 1 | 2025 | 339 | 0.050 |
Why?
|
| Program Development | 1 | 2024 | 136 | 0.050 |
Why?
|
| Filtration | 1 | 2023 | 27 | 0.050 |
Why?
|
| Genotype | 2 | 2018 | 1883 | 0.050 |
Why?
|
| Reflex | 1 | 2023 | 81 | 0.050 |
Why?
|
| Xenobiotics | 1 | 2003 | 8 | 0.050 |
Why?
|
| Neck | 1 | 2023 | 99 | 0.050 |
Why?
|
| Aspartic Acid | 1 | 2003 | 67 | 0.050 |
Why?
|
| Database Management Systems | 1 | 2003 | 44 | 0.050 |
Why?
|
| Educational Measurement | 1 | 2024 | 246 | 0.050 |
Why?
|
| Radiation Dosage | 1 | 2023 | 236 | 0.050 |
Why?
|
| Infant, Newborn | 4 | 2019 | 2611 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2007 | 1962 | 0.050 |
Why?
|
| Proteomics | 1 | 2024 | 268 | 0.050 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2024 | 189 | 0.040 |
Why?
|
| Phantoms, Imaging | 1 | 2023 | 490 | 0.040 |
Why?
|
| Methylprednisolone | 1 | 2020 | 68 | 0.040 |
Why?
|
| Health Personnel | 1 | 2023 | 241 | 0.040 |
Why?
|
| Endpoint Determination | 1 | 2020 | 59 | 0.040 |
Why?
|
| Movement Disorders | 1 | 2020 | 45 | 0.040 |
Why?
|
| Energy Metabolism | 1 | 2003 | 312 | 0.040 |
Why?
|
| Sensation | 1 | 2020 | 52 | 0.040 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2014 | 308 | 0.040 |
Why?
|
| Adolescent | 4 | 2020 | 9878 | 0.040 |
Why?
|
| College Admission Test | 1 | 2020 | 2 | 0.040 |
Why?
|
| Histones | 2 | 2013 | 362 | 0.040 |
Why?
|
| Suppositories | 1 | 2019 | 4 | 0.040 |
Why?
|
| Abbreviated Injury Scale | 1 | 2019 | 12 | 0.040 |
Why?
|
| New York City | 1 | 2020 | 69 | 0.040 |
Why?
|
| Hypotension | 2 | 2019 | 76 | 0.040 |
Why?
|
| Mobility Limitation | 1 | 2019 | 20 | 0.040 |
Why?
|
| Skin Ulcer | 1 | 2019 | 27 | 0.040 |
Why?
|
| School Admission Criteria | 1 | 2020 | 31 | 0.040 |
Why?
|
| Urinary Catheterization | 1 | 2019 | 40 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2019 | 35 | 0.040 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2019 | 30 | 0.040 |
Why?
|
| Consensus | 1 | 2021 | 372 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 140 | 0.040 |
Why?
|
| Protein Binding | 2 | 2014 | 1560 | 0.040 |
Why?
|
| Clinical Competence | 1 | 2024 | 858 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2025 | 1087 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2003 | 631 | 0.040 |
Why?
|
| Infant | 3 | 2019 | 3359 | 0.040 |
Why?
|
| Molecular Sequence Data | 2 | 2013 | 3040 | 0.030 |
Why?
|
| Blood Platelets | 1 | 2019 | 154 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 468 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2023 | 1166 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 358 | 0.030 |
Why?
|
| Child, Preschool | 3 | 2019 | 3969 | 0.030 |
Why?
|
| Pneumonia | 1 | 2019 | 196 | 0.030 |
Why?
|
| Young Adult | 2 | 2020 | 7034 | 0.030 |
Why?
|
| Family Health | 1 | 2017 | 159 | 0.030 |
Why?
|
| Mass Screening | 1 | 2022 | 710 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 935 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2017 | 100 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2017 | 120 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 936 | 0.030 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2016 | 6 | 0.030 |
Why?
|
| Lung | 1 | 2023 | 1380 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2018 | 235 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2019 | 425 | 0.030 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2016 | 38 | 0.030 |
Why?
|
| Logistic Models | 1 | 2020 | 1273 | 0.030 |
Why?
|
| Government Regulation | 1 | 2016 | 50 | 0.030 |
Why?
|
| Confidentiality | 1 | 2016 | 79 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2017 | 296 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 2042 | 0.030 |
Why?
|
| Length of Stay | 1 | 2019 | 835 | 0.030 |
Why?
|
| Pedigree | 1 | 2017 | 978 | 0.030 |
Why?
|
| Estrogen Receptor alpha | 1 | 2017 | 155 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2017 | 703 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 1079 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2017 | 220 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2018 | 776 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2017 | 255 | 0.030 |
Why?
|
| Depression | 1 | 2019 | 562 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2016 | 161 | 0.030 |
Why?
|
| Pharmacogenetics | 1 | 2019 | 457 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 7224 | 0.030 |
Why?
|
| Hematoma | 2 | 1985 | 109 | 0.030 |
Why?
|
| Nucleotide Motifs | 1 | 2014 | 49 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2018 | 556 | 0.030 |
Why?
|
| Neural Pathways | 1 | 2016 | 333 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 1880 | 0.030 |
Why?
|
| Health Records, Personal | 1 | 2013 | 11 | 0.030 |
Why?
|
| Trauma Severity Indices | 1 | 2013 | 47 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 799 | 0.030 |
Why?
|
| Penetrance | 1 | 2013 | 48 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 2498 | 0.030 |
Why?
|
| Dioxygenases | 1 | 2013 | 82 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 2013 | 163 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2014 | 393 | 0.020 |
Why?
|
| Inpatients | 1 | 1996 | 348 | 0.020 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2012 | 13 | 0.020 |
Why?
|
| U937 Cells | 1 | 2012 | 32 | 0.020 |
Why?
|
| Cytosine | 1 | 2013 | 135 | 0.020 |
Why?
|
| K562 Cells | 1 | 2012 | 49 | 0.020 |
Why?
|
| Publishing | 1 | 2014 | 94 | 0.020 |
Why?
|
| Trauma Centers | 1 | 2013 | 174 | 0.020 |
Why?
|
| Haploinsufficiency | 1 | 2012 | 69 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2012 | 215 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2012 | 279 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 2012 | 250 | 0.020 |
Why?
|
| Risk Factors | 1 | 2022 | 5992 | 0.020 |
Why?
|
| Cerebral Hemorrhage | 2 | 1985 | 374 | 0.020 |
Why?
|
| RNA Interference | 1 | 2012 | 385 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2012 | 522 | 0.020 |
Why?
|
| Insulator Elements | 1 | 2011 | 7 | 0.020 |
Why?
|
| Silencer Elements, Transcriptional | 1 | 2011 | 7 | 0.020 |
Why?
|
| Histone Code | 1 | 2011 | 19 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 796 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 528 | 0.020 |
Why?
|
| RNA, Small Untranslated | 1 | 2010 | 15 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 897 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 301 | 0.020 |
Why?
|
| Acute Disease | 1 | 2012 | 859 | 0.020 |
Why?
|
| Nucleosomes | 1 | 2010 | 63 | 0.020 |
Why?
|
| Histone Deacetylases | 1 | 2011 | 86 | 0.020 |
Why?
|
| Genes, Insect | 1 | 2010 | 184 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 1959 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2013 | 2928 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2012 | 2160 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 2042 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2012 | 2776 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2010 | 555 | 0.020 |
Why?
|
| Birth Injuries | 1 | 1985 | 4 | 0.010 |
Why?
|
| Orbital Fractures | 1 | 1985 | 13 | 0.010 |
Why?
|
| Mastoid | 1 | 1985 | 16 | 0.010 |
Why?
|
| Skull Fractures | 1 | 1985 | 28 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 2495 | 0.010 |
Why?
|
| Brain Edema | 1 | 1985 | 61 | 0.010 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 1985 | 154 | 0.010 |
Why?
|
| Brain Concussion | 1 | 1985 | 88 | 0.010 |
Why?
|
| Choline | 1 | 2003 | 27 | 0.010 |
Why?
|
| Creatine | 1 | 2003 | 28 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2003 | 236 | 0.010 |
Why?
|
| Mice | 1 | 2012 | 12525 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 2 | 1985 | 2777 | 0.010 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 1998 | 179 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 1998 | 273 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 1998 | 231 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 1996 | 88 | 0.010 |
Why?
|
| Evoked Potentials | 1 | 1977 | 202 | 0.010 |
Why?
|
| Cerebrovascular Disorders | 1 | 1996 | 146 | 0.010 |
Why?
|
| Brain Diseases | 1 | 1996 | 193 | 0.010 |
Why?
|
| Cognition | 1 | 1998 | 635 | 0.010 |
Why?
|
| Contrast Media | 1 | 1998 | 1097 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 1977 | 615 | 0.010 |
Why?
|
| Biomarkers | 1 | 1998 | 1931 | 0.010 |
Why?
|
| Haplorhini | 1 | 1977 | 81 | 0.000 |
Why?
|
| Electric Stimulation | 1 | 1977 | 398 | 0.000 |
Why?
|
| Hypertension | 1 | 1977 | 775 | 0.000 |
Why?
|